Factors associated with glucocorticoid dosing in treating patients with noncritical COVID-19 pneumonia: Insights from...

Glucocorticoids are vital in treating COVID-19, but standard dosage for noncritical patients remain controversial. To determine the optimal glucocorticoid dosage for noncritical COVID-19 patients, we analyzed factors influencing dosage and developed a predictive model.

We retrospectively analyzed 273 noncritical COVID-19 pneumonia patients underwent pulmonary CT and treated with glucocorticoids in a tertiary hospital (12/2022-01/2023). Patients were divided into low and high glucocorticoid dosage groups based on a daily 40mg methylprednisolone or equivalent. Artificial intelligence (AI)-based deep learning was utilized to assess pulmonary CT images for accurate lesion area, which then analyzed through multivariable logistic regression to explore their correlation with glucocorticoid dosage. A predictive model was developed and validated for dosage prediction.

The primary analysis included 243 patients, with 168 in the training set and 75 in the validation set. High-dose treatment was administered to 139 patients (82.7%) and low-dose to 29 patients (17.3%) in the training cohort. A predictive model incorporating normally inflated ratio, ground-glass opacity (GGO) ratio, and consolidation ratio accurately predicted selection of high- or low-dose, in both training (AUC=0.803) and validation cohorts (AUC=0.836), respectively. In 30 patients with post-CT adjusted dosages, the predicted dosages highly matched with the actual adjusted dosages.

Glucocorticoid dosages for noncritical COVID-19 pneumonia treatment are influenced by pulmonary CT features. Our predictive model can predict glucocorticoid dosage, however, should be validated by larger, prospective studies.